Cybin

Cybin Inc (NYSEAMERICAN: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company on the frontier of developing psychedelic-based therapies, provided updates on its ongoing clinical trials evaluating its proprietary deuterated molecules of a psilocybin analog known as CYB003, and CYB004 DMT....

Cybin Inc (NYSEAMERICAN: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company on the frontier of developing psychedelic-based therapies, will provide updates on its ongoing clinical trials evaluating its proprietary deuterated molecules of a psilocybin analog known as CYB003, and CYB004...

Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E...

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. (OTCQB: MSSTF) for an exclusive intellectual property license related to...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. Drug Enforcement Agency (DEA) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog being...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the treasury to the public. Cybin’s shares distributions will be handled through agents...

This article was originally published on Cannabis & Tech Today and appears here with permission. Cannabis legalization is opening the floodgates for alternative medicines. Ketamine in particular is showing promise and one company is taking a novel approach to researching the drug. Kernel,...

Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Doug Drysdale, CEO, Cybin Inc. (NYSE: CYBN) was a guest speaker at Benzinga’s Psychedelic Capital...

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to its next phase. Clinilabs is to carry out Cybin’s Phase 1/2a clinical trial of CYB003 for...

CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and substance abuse disorders. According to the company, the substance has recently shown positive preclinical data over DMT, the molecule from which it is derived. Cybin...

Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules. “Our progress to secure IP for unique psychedelic delivery methods strongly...

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,...

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. (NYSE: CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without...

Cybin Inc. (NYSE: CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. The goal is to analyze the potential of the compound in treating major depressive disorder (MDD). The studies were carried out on multiple species and included several...

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second...